Global funding trends for malaria research in sub-Saharan Africa: a systematic analysis.
Global funding trends for malaria research in sub-Saharan Africa: a systematic analysis.
复制标题
撒哈拉以南非洲疟疾研究的全球资金趋势：系统分析。
DOI：
10.1016/s2214-109x(17)30245-0
复制
发表时间：
2017-08
期刊：
影响因子：
--
通讯作者：
Tatem AJ
中科院分区：
文献类型：
--
作者：
Head MG;Goss S;Gelister Y;Alegana V;Brown RJ;Clarke SC;Fitchett JRA;Atun R;Scott JAG;Newell ML;Padmadas SS;Tatem AJ
用于疟疾的国内和国际资金总额不足以实现世卫组织到2030年减轻负担的全球目标。我们描述了撒哈拉以南非洲疟疾相关研究的投资趋势，并将投资与国家疾病负担进行比较，以确定资金实力和潜在被忽视人群的领域。我们还考虑了为控制疟疾提供资金的问题。1997-2013年与疟疾有关的研究资金数据来自现有数据集、13个主要公共和慈善全球卫生资助者以及资金数据库。按地理区域审议了投资（以美元报告），并将其与撒哈拉以南非洲的寄生虫流行率和风险人口数据进行了比较。45个撒哈拉以南非洲国家按收到的研究经费数额进行了排名。我们发现了333项研究奖项，总额为8.144亿美元。公共卫生研究涉及3.081亿美元（37.8%），临床试验涉及2.752亿美元（33.8%）。坦桑尼亚（1.078亿美元[13.2%]）、乌干达（9790万美元[12.0%]）和肯尼亚（9290万美元[11.4%]）获得了最高的研究投资和最多的研究奖项。马拉维、坦桑尼亚和乌干达在按国内生产总值调整后仍然排名靠前。疟疾负担相当高但几乎没有获得疟疾控制研究投资或资金的国家包括中非共和国（排名第40位）和塞拉利昂（排名第35位）。刚果（布拉柴维尔）和几内亚的疟疾死亡率相当高，但刚果（布拉柴维尔）排在第38位，几内亚排在第25位，因此得到的投资很少。一些国家在与疟疾有关的研究方面得到相当大的投资（坦桑尼亚、肯尼亚、乌干达），而另一些国家得到的投资很少或根本没有（塞拉利昂、中非共和国）。在疟疾控制资金也很高的国家，研究投资通常最高。投资战略应考虑在各国进行更公平的研究和业务投资，以包括目前被忽视和易受影响的人口。皇家热带医学和卫生学会和比尔及梅林达盖茨基金会。
Total domestic and international funding for malaria is inadequate to achieve WHO global targets in burden reduction by 2030. We describe the trends of investments in malaria-related research in sub-Saharan Africa and compare investment with national disease burden to identify areas of funding strength and potentially neglected populations. We also considered funding for malaria control. Research funding data related to malaria for 1997–2013 were sourced from existing datasets, from 13 major public and philanthropic global health funders, and from funding databases. Investments (reported in US$) were considered by geographical area and compared with data on parasite prevalence and populations at risk in sub-Saharan Africa. 45 sub-Saharan African countries were ranked by amount of research funding received. We found 333 research awards totalling US$814·4 million. Public health research covered $308·1 million (37·8%) and clinical trials covered $275·2 million (33·8%). Tanzania ($107·8 million [13·2%]), Uganda ($97·9 million [12·0%]), and Kenya ($92·9 million [11·4%]) received the highest sum of research investment and the most research awards. Malawi, Tanzania, and Uganda remained highly ranked after adjusting for national gross domestic product. Countries with a reasonably high malaria burden that received little research investment or funding for malaria control included Central African Republic (ranked 40th) and Sierra Leone (ranked 35th). Congo (Brazzaville) and Guinea had reasonably high malaria mortality, yet Congo (Brazzaville) ranked 38th and Guinea ranked 25th, thus receiving little investment. Some countries receive reasonably large investments in malaria-related research (Tanzania, Kenya, Uganda), whereas others receive little or no investments (Sierra Leone, Central African Republic). Research investments are typically highest in countries where funding for malaria control is also high. Investment strategies should consider more equitable research and operational investments across countries to include currently neglected and susceptible populations. Royal Society of Tropical Medicine and Hygiene and Bill & Melinda Gates Foundation.
影响因子：
4
作者：
Adam T;Røttingen JA;Kieny MP
通讯作者：
Kieny MP